REGENXBIO Inc. 8-K

What Happened REGENXBIO Inc. announced on Form 8-K (filed March 20, 2026) that it entered into a Settlement and Release Agreement with GlaxoSmithKline LLC on March 18, 2026 to resolve a dispute over sublicense fees under the March 6, 2009 license (as amended). Under the agreement, REGENXBIO will pay $10.0 million to GSK for alleged underpayment of sublicense fees on amounts received from sublicensees, including royalties.

Key Details

• Settlement entered March 18, 2026; 8-K filed March 20, 2026.
• REGENXBIO to pay $10.0 million to GSK within three business days of the Settlement Agreement’s effective date.
• Mutual releases: all past claims related to the GSK-REGENXBIO sublicense and certain specified future claims are released.
• REGENXBIO will continue to remit amounts from sublicensees under existing agreements using its current allocation methodology; the full Settlement Agreement will be filed with REGENXBIO’s 10-Q for the quarter ending March 31, 2026.

Why It Matters This resolves a previously disclosed dispute over sublicense fee payments, removes related past claims, and requires an immediate cash payment of $10.0 million. For investors, the settlement clarifies the company’s obligations under its GSK sublicense and limits future litigation risk tied to these specific claims, while confirming ongoing royalty/sublicense payment practices.